Cardiometabolic Disease and COVID-19: Risk, Treatment and Trials

The effect of COVID and metabolic disease and early treatment

Dr Mikhail N Kosiborod (Saint Luke's America Heart Institute, Kansas City, US) joins Prof Hertzel Gerstein (McMaster University, Hamilton, ON, CA) to discuss the current landscape of cardiometabolic therapies for COVID-19. Dr Kosiborod talks about the cardiometabolic risk factors for death in people who are hospitalised with COVID-19.
Recoded remotely from Hamilton and Kansas City, 2020.
This discussion was supported by an unrestricted educational grant from Novo Nordisk.

Mikhail Kosiborod

Dr Kosiborod is an internationally recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, and quality care and outcomes.

Hertzel C Gerstein

Dr Hertzel C Gerstein is an Endocrinologist and Professor at McMaster University and Hamilton Health Sciences, where he holds the Population Health Institute Chair in Diabetes Research.

Programme Outline

The effect of COVID and metabolic disease and early treatmentMikhail KosiborodHertzel C Gerstein
Metabolic therapy treatmentsMikhail KosiborodHertzel C Gerstein
Phase III DARE-19 trialMikhail KosiborodHertzel C Gerstein

This discussion was supported by an unrestricted educational grant from Novo Nordisk.

Metabolic therapy treatments

Play Next

Search form

The effect of COVID and metabolic disease and early treatment

Metabolic therapy treatments